Amarin Corp Plc (AMRN)

[chas1232123]

To try to salvage a bit more from the US market, how about a DAW (dispense as written) campaign? Amarin could send brief messages to doctors appealing to their sense of fairness. It could be an extra line or two at the bottom of a medical journal ad. Point out that, with generics using a loophole to enter the market long before Amarin recoups their development costs, there's inadequate funding to educate doctors and promptly deploy life-saving Vascepa. Generics don't do that, they assume it's already be done. Adding DAW to Vascepa prescriptions would help fund gett the word out, would help preserve the incentives needed for drug dingevelopment generally, and it's just the right thing to do. Patients with insurance would not pay any more.

Just a thought. If 10% of high prescribers did that, seems like it might help a bit.